Non-canonical activity of retinoic acid in relation to the activation of protein kinases in transformed cells of different origin

Background. The non-canonical activity of retinoic acid (RA) was discovered relatively recently and consists in the rapid activation of intracellular signaling pathways by the mechanisms not related to the transcriptional activity of the RA nuclear receptors. Separate data suggest that this activity can stimulate the processes of malignancy and contribute to the formation of tumor cell resistance to RA as a therapeutic agent. However, little is known about the mechanisms of this activity. It is also unclear how universal this effect is; does the RA-dependent activation of different signaling protein kinases occur in the same cells, and whether activation of these kinases is interrelated.

Materials and methods: cultivation of non-small cell lung cancer cells and neuroblastoma cells under standard conditions and with incubation with all-trans retinoic acid (ATRA); immunoblotting.

Results. Here we studied the effect of ATRA on the activation of Akt and Erk1/2 protein kinases depending on the incubation time. The analysis revealed RA-dependent activation of both kinases in all studied non-small cell lung cancer and neuroblastoma cell lines. Activation of Akt and Erk1/2 occurred at five minutes of incubation, which corresponds to the non-transcriptional (non-canonical) activity of the RA, however, further activation kinetics of the two kinases differed essentially.

Conclusion. We found that ATRA causes rapid activation of Erk1/2 and Akt protein kinases in both non-small cell lung cancer and neuroblastoma cells. The differences in the kinetics of RA-dependent stimulation of these two kinases suggest that their activation is mediated by independent mechanisms.

1. Bushue N., Wan YJ.Y. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2.010;62(13):1285—98. DOI: 10.1016/j.addr.2010.07.003. PMID: 20654663.

2. Connolly R.M., Nguyen N.K., Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 2013;19(7):1651—9. DOI: 10.1158/1078-0432.CCR-12-3175. PMID: 23322901.

3. Garattini E., Gianni M., Terao M. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 2007;13(13):1375—400. PMID: 17506722. http://www.ncbi.nlm.nih.gov/pubmed/17506722.

4. Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu Rev Nutr 2004;24:201-21. DOI: 10.1146/an-nurev.nutr.24.012003.132407. PMID: 15189119.

5. Freemantle S.J., Spinella M.J., Dmitro-vsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22(47):7305—15. DOI: 10.1038/sj.onc.1206936. PMID: 14576840.

6. Persaud S.D., Lin Y.W., Wu C.Y. et al. Cellular retinoic acid binding protein I mediates rapid non-canonical activation of Erk1/2 by all-trans retinoic acid. Cell Signal 2013;25(1):19—25. DOI: 10.1016/j.cellsig.2012.09.002. PMID: 22982089.

7. Persaud S.D., Park S.W., Ishigami-Yuasa M. et al. All trans-retinoic acid analogs promote cancer cell apoptosis through nongenomic Crabp1 mediating Erk1/2 phosphorylation. Sci Rep 2016;6:22396. DOI: 10.1038/srep22396. PMID: 26935534.

8. Quintero Barceinas R.S., Garcia-Regala-do A., Arechaga-Ocampo E. et al. All-trans retinoic acid induces proliferation, survival, and migration in A549 lung cancer cells by activating the Erk signaling pathway through a transcription-independent mechanism. Biomed Res Int 2015;2015:404368. DOI: 10.1155/2015/404368. PMID: 26557664.

9. Alsayed Y., Uddin S., Mahmud N. et al. Activation of Rac1 and the p38 mitogenactivated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001;276(6):4012—9. DOI: 10.1074/jbc.M007431200. PMID: 11060298.

10. Masia S., Alvarez S., de Lera A.R. et al. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol Endocrinol 2007;21(10):2391 —402. DOI: 10.1210/me.2007-0062. PMID: 17595318.

11. Piskunov A., Rochette-Egly C. A retinoic acid receptor RARa pool present in membrane lipid rafts forms complexes with G protein aQ to activate p38MAPK. Oncogene 2012;31(28):3333—45. DOI: 10.1038/onc.2011.499. PMID: 22056876.

12. Garcia-Regalado A., Vargas M., Garcia-Carranca A. et al. Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells. Mol Cancer 2013;12:44. DOI: 10.1186/1476-4598-12-44. PMID: 23693014.

13. Bruck N., Vitoux D., Ferry C. et al. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J 2009;28(1):34-47. DOI: 10.1038/emboj.2008.256. PMID: 19078967.